You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Yervoy

Showing 1 - 25 of 376
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Yervoy Pregnancy Surveillance Study

Withdrawn
  • Melanoma
  • Yervoy
  • Baltimore, Maryland
    UBC
Mar 16, 2022

Yervoy® Postmarketing Surveillance for Japan With Unresectable,

Completed
  • Melanoma
    • Chiyoda-ku, Tokyo, Japan
    • +1 more
    Feb 11, 2022

    Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma

    Recruiting
    • Mesothelioma, Malignant
      • Shinjuku-ku, Tokyo, Japan
        Local Institution
      Apr 5, 2022

      Advanced Renal Cell Carcinoma Trial (Botensilimab, Balstilimab, Ipilimumab)

      Not yet recruiting
      • Advanced Renal Cell Carcinoma
      • (no location specified)
      Jun 23, 2023

      Breast Cancer Trial in Boston, Pittsburgh, Dallas (Nivolumab, Ipilimumab)

      Active, not recruiting
      Has Results
      • Breast Cancer
      • Boston, Massachusetts
      • +2 more
      Oct 21, 2022

      NSCLC Trial in Durham (Nivolumab, Ipilimumab, Paclitaxel)

      Active, not recruiting
      • Non-small Cell Lung Cancer
      • Durham, North Carolina
        Duke University Medical Center
      Apr 22, 2022

      Metastatic Melanoma, Skin Cancer Trial in Boston (Ipilimumab, Nivolumab, Cryoablation)

      Not yet recruiting
      • Metastatic Melanoma
      • Skin Cancer
      • Boston, Massachusetts
        Massachusetts General Hospital Cancer Center
      Mar 9, 2023

      Solid Tumor, Solid Tumor, Adult Trial (Sargramostim, Ipilimumab-containing therapy)

      Suspended
      • Solid Tumor
      • Solid Tumor, Adult
      • Sargramostim
      • Ipilimumab-containing therapy
      • Lexington, Massachusetts
        Partner Therapeutics - No Currently Active Sites
      Nov 30, 2022

      Squamous Cell Carcinoma of the Head and Neck Trial in Portland (Intratumoral Ipilimumab)

      Active, not recruiting
      • Squamous Cell Carcinoma of the Head and Neck
      • Intratumoral Ipilimumab
      • Portland, Oregon
        Portland Providence Medical Center
      Jan 8, 2023

      Melanoma Trial in Tampa (Ipilimumab, Axitinib)

      Recruiting
      • Melanoma
      • Tampa, Florida
        Moffitt Cancer Center
      Jun 21, 2022

      Metastatic Uveal Melanoma Trial in Grand Rapids (IDE196, Crizotinib, Pembrolizumab)

      Recruiting
      • Metastatic Uveal Melanoma
      • Grand Rapids, Michigan
        The Cancer and Hematology Centers
      Aug 14, 2023

      Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant

      Recruiting
      • Atypical Teratoid Rhabdoid Tumor
      • +6 more
      • Boston, Massachusetts
      • +1 more
      Jan 23, 2023

      Thyroid Cancer Trial in Boston (Nivolumab, Ipilimumab)

      Active, not recruiting
      • Thyroid Cancer
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Feb 18, 2022

      Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

      Not yet recruiting
      • Metastatic Nasopharyngeal Carcinoma
      • +2 more
      • Nivolumab
      • +5 more
      • (no location specified)
      Aug 21, 2023

      Mucinous Tumor, Colorectal Tumor, Appendiceal Tumor Trial in Philadelphia (Nivolumab, Ipilimumab)

      Terminated
      Has Results
      • Mucinous Adenocarcinoma of the Colon
      • Mucinous Adenocarcinoma of the Rectum
      • Philadelphia, Pennsylvania
        Abramson Cancer Center of the University of Pennsylvania
      Sep 26, 2022

      Observe Onset of Immune-related Adverse Reactions in

      Completed
      • Renal Cell Carcinoma
      • Kidney Cancer
      • Non-Interventional
      • Tokyo, Japan
        Local Institution
      Feb 9, 2022

      Metastatic Urothelial Carcinoma Trial in Tampa, Boston (Ipilimumab, Nivolumab, Sacituzumab govitecan)

      Recruiting
      • Metastatic Urothelial Carcinoma
      • Tampa, Florida
        Moffitt Cancer Center
      Jan 24, 2023

      Malignant Melanoma Trial in Herlev, Aarhus, Odense (Pembrolizumab Injection [Keytruda], Ipilimumab Injection [Yervoy], Nivolumab

      Recruiting
      • Malignant Melanoma
      • Pembrolizumab Injection [Keytruda]
      • +6 more
      • Herlev, Hovedstaden, Denmark
      • +2 more
      Sep 16, 2022

      Lung Cancer Metastatic Trial in Durham (Nivolumab, Ipilimumab, Evolocumab)

      Recruiting
      • Lung Cancer Metastatic
      • Durham, North Carolina
        Duke Univ. Medical Center
      May 16, 2022

      Melanoma Trial in New York (Nivolumab, Ipilimumab)

      Completed
      Has Results
      • Melanoma
      • Nivolumab
      • Ipilimumab
      • New York, New York
        Laura and Isaac Perlmutter Cancer Center
      Aug 11, 2022

      Head Neck Cancer Trial in Boston (Nivolumab, Ipilimumab, Standard of Care Surgery)

      Active, not recruiting
      Has Results
      • Head and Neck Cancer
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Feb 22, 2022

      Melanoma Trial in Boston (Bevacizumab Plus Ipilimumab Cohort 1, Bevacizumab Plus Ipilimumab Cohort 2, Bevacizumab Plus

      Active, not recruiting
      • Melanoma
      • Bevacizumab Plus Ipilimumab Cohort 1
      • +3 more
      • Boston, Massachusetts
      • +2 more
      Nov 8, 2021

      Nasopharyngeal Carcinoma Trial in Singapore (Ipilimumab, Nivolumab)

      Recruiting
      • Nasopharyngeal Carcinoma
      • Singapore, Singapore
        National Cancer Center Singapore
      Jul 20, 2022

      Neuroblastoma, Pediatric Solid Tumor Trial in Boston (procedure, biological, drug)

      Recruiting
      • Neuroblastoma
      • Pediatric Solid Tumor
      • Tissue collection
      • +3 more
      • Boston, Massachusetts
      • +1 more
      Oct 17, 2022

      Locally Advanced Pancreatic Cancer (LAPC) Trial in Herlev (Gemcitabine, Nab-paclitaxel, Nivolumab)

      Recruiting
      • Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer
      • Herlev, Denmark
        Herlev & Gentofte University Hospital, Denmark
      Oct 13, 2022